somatrogon · NGENLA
Protein / enzyme therapeutic
Evidence outlook
Approved: Growth Hormone Deficiency
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
- Treatment of short stature due to growth hormone deficiency prior to epiphyseal closure
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03831880 NCT03831880 · Growth Hormone Deficiency Randomized crossover comparison against daily Genotropin, and the primary measure of treatment burden (overall life interference score) was significantly lower with weekly somatrogon (difference -15.49 points, p<0.0001). The study was open-label and the outcome is a questionnaire answered by families who knew which treatment they were on, and it measures injection burden rather than growth. Registry: NCT03831880 | 3 | Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire; Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire; Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire; Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire (Baseline up to Week 24) 2020-08-28 | Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Growth hormone receptor drugs
lonapegsomatropin, Somatropin, Somatropin (Jintropin). Compare all 4 Growth hormone receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Growth Hormone Deficiency: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Somatrogon (NGENLA): this drug | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | NCT03831880: Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results). | |
| Lonapegsomatropin (Skytrofa) | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | Featured results are safety and non-efficacy only in this race | |
| Somatropin (Serostim) | Approved(overall) | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Somatropin (Jintropin) | Phase 3(overall) | Biologic (subtype unspecified) | Growth hormone receptor | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow NGENLA (somatrogon) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.